Science Advances Impact Factor

Data sourced from our analysis of 20,449 journals in the Clarivate JCR 2024 database.

Source: Clarivate JCR 2024 (2024 data). All figures are official two-year journal impact factors.

Science Advances launched in 2015 and built steadily through its early years. The peak in 2021 at 15.0 reflected the same COVID-era citation surge that inflated IFs across most high-impact journals: papers from 2019 and 2020 got cited heavily as researchers quickly built on pandemic-related and adjacent work.

The 2022-2023 drop was sharp but predictable. As COVID citation inflation normalized, journals across all fields saw declines. Science Advances fell from 15.0 to 11.7 over two years, a 22% drop. That's real, but not alarming: the same pattern played out at Nature Communications, PNAS, and most multidisciplinary journals.

The 2024 recovery to 12.5 is a good sign. It suggests the journal's citation base is stabilizing rather than continuing to slide, which is the practical thing most authors want to know when they search this query.

Scopus metrics provide a complementary view to the JCR impact factor. They're especially useful for authors in systems that weight Scopus indexing or for comparing journals across different classification schemes.

The CiteScore of 19.6 runs above the two-year JIF of 12.5 because of the longer citation window. An SJR of 4.324 confirms genuine citation authority in Scopus. The h-index of 288 is remarkable for a journal launched in 2015, it means 288 papers have crossed the 288-citation threshold, putting Science Advances in the same citation-depth class as decades-older journals.

In our pre-submission review work on manuscripts targeting Science Advances, three patterns account for most of the desk rejections we see.

Interdisciplinary framing that is actually single-discipline work in disguise. Science Advances sits under the AAAS banner alongside Science itself, and it is specifically positioned as the journal for high-quality, cross-disciplinary research that does not quite reach Science's paradigm-shifting bar. The editorial filter is real: papers need to speak across disciplinary lines, not just claim they do. We see submissions in materials science, chemistry, or computational biology where the abstract says "implications for biology and medicine" but the paper is written exclusively for specialists in one field. The interdisciplinary framing needs to be in the content, not the cover letter. Readers from adjacent disciplines should be able to follow the paper's logic and understand its importance without deep specialization.

Technically sound papers without broader significance framing. Science Advances desk-rejects roughly 40% of submissions at the editorial stage without external review. The primary filter at triage is significance, not technical quality. We see manuscripts where the methodology is impeccable and the results are valid but the framing never addresses the question "why does this matter beyond my field?" A materials science paper that optimizes a polymer property without explaining why that optimization unlocks a new capability is missing the frame. The paper needs to connect the technical result to a broader consequence that scientists outside the subfield can recognize as important.

Submissions that belong in Science but are preemptively self-downgraded. The most interesting pattern we see is strong papers submitted to Science Advances by authors who conclude their work is "not quite Science-level" without rigorous self-assessment. Science Advances is a strong journal, but it is not Science, and submitting to Science Advances when the paper could compete for Science costs the author prestige and community visibility. We see this most often with interdisciplinary papers that have a genuinely surprising or field-reframing finding but get submitted to Science Advances because the authors are uncertain about the Science bar. A pre-submission assessment of whether the finding actually changes how scientists in multiple fields think can resolve that uncertainty before submission.

For most research evaluation contexts, an IF of 12.5 puts Science Advances in a clear tier:

• Clear top-tier: Nature/Science/Cell and their flagship siblings (IF 30+)
• Strong high-impact: Nature Communications, Science Advances, PNAS, PLOS Biology (IF 8-20)
• Solid specialist journals: Cell Reports, Nucleic Acids Research, JCI (IF 6-14)
• Broad-scope journals: Scientific Reports, PLOS ONE (IF 2-6)

For hiring committees and grant reviewers in most biomedical and physical science fields, a Science Advances paper reads as a solid high-impact publication. It's not a CNS paper, but it's well above the noise.

For tenure and promotion cases specifically, the journal's open-access nature is increasingly a positive signal rather than a neutral one, particularly at institutions with strong OA commitments.

It's a fair question. The drop from 15.0 to 11.7 over 2021-2023 was steep enough that some researchers started treating Science Advances as a lower-tier target than they had before.

The 2024 recovery to 12.5 is encouraging, but one year of data doesn't confirm a trend. A few things suggest the floor is behind us:

• Science Advances still publishes ~3,000 papers per year with strong methodological quality
• AAAS brand strength hasn't changed: this is still the organization that publishes Science itself
• Post-COVID IF normalization has stabilized across most journals in the 2023-2024 window
• The 5-year IF sits at approximately 14.1, which better reflects the journal's long-term citation performance

For most researchers, the 2024 figure of 12.5 is the one to use. The historical peak at 15.0 is not coming back in the near term, and the 11.7 from 2023 was likely the trough.

2025 outlook: Given the 2024 stabilization at 12.5 and article volume holding at ~2,200 per year, the 2025 IF is likely to land in the 12-13 range. No structural changes to the journal's editorial model or AAAS's publishing strategy suggest a significant shift.

Indexing: Science Advances is indexed in PubMed/MEDLINE, Scopus (Q1), Web of Science (SCIE), DOAJ, and Google Scholar. All articles are published under CC BY 4.0 license.

AAAS publishes a family of journals under the Science brand. If your paper doesn't clear the Science Advances bar, or if it fits a more specialized scope, the AAAS portfolio has options. Editors sometimes suggest transfers between these journals during review.

Science Advances is the volume workhorse of the AAAS portfolio. It publishes roughly 3x more papers than all the other Science siblings combined, which is partly why its IF sits lower than Science Translational Medicine or Science Immunology. Those journals are narrower and more selective, so their citation density runs higher per paper.

The practical implication: if your manuscript is strong but doesn't have the paradigm-shifting novelty for Science itself, Science Advances is the natural fallback within the AAAS system. If your work is clearly translational medicine or immunology, you're better off targeting those specialized siblings directly, they carry higher IFs and more focused editorial expertise.

Submit to Science Advances if your paper meets most of these:

• [ ] The work crosses disciplinary boundaries or has clear implications beyond your specialty
• [ ] Your result would interest scientists in at least two different fields
• [ ] You can write a 2-sentence statement explaining why the finding matters outside your subfield
• [ ] Your institution has AAAS journal coverage, or you can cover the $5,000 APC
• [ ] The AAAS brand carries particular weight in your field (common in physical and interdisciplinary sciences)
• [ ] You're comfortable with a 21-28 day decision timeline
• [ ] Your paper is complete - Science Advances has limited appetite for "first report" papers without mechanistic follow-through

Do not submit if:

• Your paper is a strong advance within one specialty but doesn't cross fields (Nature Communications is the better call)
• Your institution has Springer Nature coverage but no AAAS agreement (Nature Communications becomes significantly cheaper in practice)
• Your work is primarily clinical or epidemiological (PNAS or field-specific journals are better fits)

The honest comparison with PNAS: Both are AAAS portfolio journals targeting similar manuscripts. Science Advances has a higher IF (12.5 vs 9.1) but PNAS is cheaper ($0-1,830 APC vs $5,000). For most multidisciplinary biology papers, PNAS is more cost-effective at comparable prestige. If AAAS journal coverage is important but cost isn't the constraint, Science Advances offers the brand with faster turnaround.

The JCI of 2.82 vs Nature Communications' 3.34 tells the honest story: Science Advances is close to Nature Communications in citation performance but not quite at the same level. The gap is narrowing, though. In 2020 the difference was larger.

Understanding the IF alone won't tell you whether your paper survives here. The editorial structure matters, and it's different from what most authors expect.

Science Advances uses roughly 50 deputy editors (DEs) and 350+ associate editors (AEs), all of whom are active research scientists, not full-time professional editors. This is a critical distinction from Nature Communications, where full-time PhD editors handle triage. At Science Advances, your paper lands on the desk of a working scientist who handles 50-100 manuscripts per month alongside their own research. They have to be efficient, which means triage decisions are fast and sometimes blunt.

The journal processes 400+ new manuscripts per week. About 90% of the ~20,000 annual submissions are rejected, most without review. Desk rejection speed is inconsistent: 2-9 days when the decision is clear-cut, but author-reported data shows some cases stretching to 56-87 days. Appeals on desk rejections are not considered, this is final.

The most common desk-reject triggers we've seen in manuscripts targeting Science Advances through our Science Advances submission readiness check: the significance case doesn't travel beyond one specialist audience, the title and abstract overstate the contribution, the comparison to prior work is inadequate, or the figures don't tell the story on their own. One pattern worth noting: editors have acknowledged rejecting papers where "the science had real significance, but the editors and reviewers could not see it." Framing is not optional at this journal.

Science Advances operates under AAAS editorial standards, which shape what reviewers focus on:

1. Cross-disciplinary framing. Science Advances wants papers that matter beyond one subfield. Reviewers push authors to explain why a chemist, biologist, or physicist outside the immediate area would care. If you can't answer that in two sentences, rethink the submission.
2. Complete datasets. Reviewers expect all data to be available. Not "data available upon request" but deposited in a public repository with an accession number. Science Advances enforces this more strictly than many journals.
3. Reproducibility documentation. Detailed methods, code availability, and clear descriptions of analytical pipelines. Reviewers at AAAS journals have become stricter on this since the replication crisis.
4. Concise writing. Science Advances values efficiency. Reviewers flag repetitive discussion sections and overly long introductions. If you can say it in 3,000 words, don't use 5,000.
5. Visual communication. Figures are expected to carry the narrative. Reviewers comment on figure quality more at AAAS journals than at most competitors. Invest in your figures.

If your cross-disciplinary case feels clear to you but your title still leads with subfield terminology, a cross-disciplinary framing check identifies where the Science Advances editor would stop reading before you find out in 2-9 days.